Tag - MBRX

Developments

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech (NASDAQ:MBRX) announced it has amended the protocol with the FDA for its Phase 3 pivotal MIRACLE trial, evaluating Annamycin in combination with Cytarabine for treating patients with acute myeloid...

November 14, 2024

Developments

Moleculin Biotech gets FDA rare pediatric disease designation for three indications

Moleculin Biotech’s (NASDAQ:MBRX) WP1066 received FDA rare pediatric disease indication for the treatment of diffuse intrinsic pontine glioma (DIPG), medulloblastoma and atypical teratoid rhabdoid tumor. WP1066 is an...

December 1, 2020

Markets

Maxim resumes coverage of Moleculin Biotech at buy; PT $3

Maxim Group resumed coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.11 on June 5. On May 1, the SEC suspended trading in Moleculin, citing questions about the...

June 8, 2020

Developments

Moleculin Biotech completes enrollment in lymphoma clinical trial

Moleculin Biotech (NASDAQ:MBRX) has completed patient enrollment in its proof-of-concept trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL). WP1220 is a topical treatment designed to inhibit p-STAT3...

August 14, 2019

Tag - MBRX

Moleculin amends protocol for Phase 3 trial of Annamycin for AML

Moleculin Biotech gets FDA rare pediatric disease designation for three indications

Maxim resumes coverage of Moleculin Biotech at buy; PT $3

Moleculin Biotech completes enrollment in lymphoma clinical trial

General

More